November 17, 2009
Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors.
November 12, 2009
Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews.
June 01, 2009
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors.
April 19, 2009
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting.
April 14, 2008
Mersana Therapeutics, Inc. Presents Preclinical Data on Fumagillin-Related Anti-Angiogenic Fleximer Conjugates at American Association of Cancer Research Annual Meeting.
February 12, 2008
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
January 03, 2008
Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors.
October 24, 2007
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference.
July 12, 2007
Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors.
May 30, 2007
Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors.
May 11, 2007
Mersana Therapeutics, Inc. Announces the Appointment of Robert J. Fram, M.D. as Chief Medical Officer.
April 13, 2007
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting.
November 08, 2005
Mersana Therapeutics, Inc. Completes $21 Million Financing.
